Claims for Patent: 9,701,709

Summary for Patent: 9,701,709

Title:	2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Abstract:	The present invention relates generally to the compound:
Inventor(s):	Anderson Eric, Liu Xiaofeng, Decker Andrea
Assignee:	REATA PHARMACEUTICALS, INC.
Application Number:	US14625829
Patent Claims:	6. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an active ingredient consisting of a polymorphic form of , and'}a pharmaceutically acceptable carrier.7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is formulated for administration: orally claim 6 , intraadiposally claim 6 , intraarterially claim 6 , intraarticularly claim 6 , intracranially claim 6 , intradermally claim 6 , intralesionally claim 6 , intramuscularly claim 6 , intranasally claim 6 , intraocularly claim 6 , intrapericardially claim 6 , intraperitoneally claim 6 , intrapleurally claim 6 , intraprostatically claim 6 , intrarectally claim 6 , intrathecally claim 6 , intratracheally claim 6 , intratumorally claim 6 , intraumbilically claim 6 , intravaginally claim 6 , intravenously claim 6 , intravesicularlly claim 6 , intravitreally claim 6 , liposomally claim 6 , locally claim 6 , mucosally claim 6 , parenterally claim 6 , rectally claim 6 , subconjunctival claim 6 , subcutaneously claim 6 , sublingually claim 6 , topically claim 6 , transbuccally claim 6 , transdermally claim 6 , vaginally claim 6 , in crèmes claim 6 , in lipid compositions claim 6 , via a catheter claim 6 , via a lavage claim 6 , via continuous infusion claim 6 , via infusion claim 6 , via inhalation claim 6 , via injection claim 6 , via local delivery claim 6 , or via localized perfusion.8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is formulated for oral claim 7 , intraarterial claim 7 , intravenous or topical administration.9. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is formulated for oral administration.10. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated as a hard or soft capsule claim 6 , a tablet claim 6 , a syrup claim 6 , a suspension claim 6 , an emulsion claim 6 , a solution claim 6 , a solid dispersion claim 6 , a wafer claim 6 , or an elixir.11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated for topical administration.12. The pharmaceutical composition of claim 11 , wherein pharmaceutical composition is formulated as a lotion claim 11 , a cream claim 11 , a gel claim 11 , an oil claim 11 , an ointment claim 11 , a salve claim 11 , an emulsion claim 11 , a solution claim 11 , or a suspension.13. The pharmaceutical composition of claim 6 , wherein the amount of the active ingredient is from about 0.01% to about 5% by weight.14. A method of treating a condition associated with inflammation or oxidative stress claim 1 , selected from the group consisting of prostate cancer claim 1 , dermatitis claim 1 , sepsis claim 1 , pulmonary inflammation claim 1 , pulmonary fibrosis claim 1 , COPD claim 1 , asthma claim 1 , mucositis claim 1 , and ocular inflammation claim 1 , in a patient in need thereof claim 1 , comprising administering to the patient a therapeutically effective amount of the polymorphic form of .15. The method of claim 14 , wherein the condition is dermatitis.